What Awaits These 4 Biotech Stocks That More Than Doubled in 2025

Key Takeaways Ionis Pharmaceuticals surged 127.6% in 2025 on progress across wholly-owned programs.GPCR jumped on phase II data showing up to 15.3% placebo-adjusted weight loss for oral GLP-1 aleniglipron.KOD rallied as late-stage tarcocimab and KSI-501 advance, with multiple phase III readouts slated for 2026.After a weak first half, the drug and biotech sector regained momentum in the latter part of 2025, setting the stage for a strong year for select stocks. Improved policy clarity following most large d ...